What's Happening?
A study comparing the Hydrus Microstent (HM) and triple iStent inject W (TiSW) devices combined with phacoemulsification for glaucoma management has been conducted over a three-year period. The research
involved 105 open-angle glaucoma patients undergoing cataract surgery at a private practice in Brisbane, Australia. The study aimed to evaluate the efficacy and safety of these devices in reducing intraocular pressure (IOP) and the number of glaucoma medications required. Results showed that both devices effectively reduced IOP and medication use, with no significant differences between the two groups. At three years, the HM group experienced a mean IOP reduction of 2.6 mmHg, while the TiSW group saw a reduction of 2.0 mmHg. Both groups also showed significant reductions in medication use, with the HM group reducing from 2.3 to 1.0 medications and the TiSW group from 2.2 to 0.8 medications.
Why It's Important?
This study is important as it provides valuable insights into the long-term efficacy and safety of minimally invasive glaucoma surgery devices. The findings suggest that both the Hydrus Microstent and iStent inject W are effective options for managing glaucoma in patients undergoing cataract surgery. This information can guide ophthalmologists in selecting the most appropriate device based on patient-specific factors, such as ocular size or anticoagulation therapy. The study also highlights the potential for these devices to reduce the reliance on glaucoma medications, which can improve patient compliance and quality of life.
